Glenmark Life Sciences Share Price Target For Tomorrow, Next Week & Next Month
Glenmark Life Sciences Limited | |||
 | Price: ₹947.20 (+0.57%) | ||
| 52 Week Low: ₹850.00 52 Week High: ₹1,335.10 | |||
| Market Capital: 13,088.97 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Glenmark Life Sciences Stock Comparison: Glenmark Life Sciences vs Wockhardt | Glenmark Life Sciences vs Strides Pharma Science | Glenmark Life Sciences vs Procter & Gamble Health | Glenmark Life Sciences vs Granules India | Glenmark Life Sciences vs Rainbow Childrens Medicare | Glenmark Life Sciences vs Marksans Pharma | |||
Show Table of Contents
Glenmark Life Sciences Recent Performance
Over the past 445 trading days, the value of Glenmark Life Sciences's stock has gained ₹326.70 (+52.65%). On 07 Nov 2023, one share was worth ₹620.50 and by 29 Aug 2025, the value jumped to ₹947.20. During this period it created a highest high of ₹1335.10 and lowest low of ₹616.80.
Glenmark Life Sciences Share Price Target - Tomorrow
| Level | Value | Analysis |
|---|---|---|
| Tomorrow Target 3 | 1026.8 (+8.4%) | Price Action: Aug 2025 High |
| Tomorrow Target 2 | 1015.2 (+7.17%) | Price Action: 23 Apr 2025 Low |
| Tomorrow Target 1 | 1003.7 (+5.96%) | Price Action: 16 Jun 2025 Low |
| Current Price | 947.20 | Glenmark Life Sciences's share price as of 29 Aug 2025 |
| Stop Loss 1 | 882 (-6.89%) | Price Action: Jun 2024 High |
| Stop Loss 2 | 870.35 (-8.11%) | Price Action: Mar 2024 High |
| Stop Loss 3 | 858.5 (-9.36%) | Price Action: May 2024 High |
Summary
29 Aug 2025: Glenmark Life Sciences finished the day at ₹947.20, gaining ₹5.50 (+0.58%) in 1 day.
Our analysis for tomorrow predicts a potential movement of -9.36% to 8.40% with:
- Target prices: ₹1003.7 to ₹1026.8
- Support levels: ₹882 to ₹858.5
- Recent high: ₹957.40
- Recent low: ₹930.70
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Glenmark Life Sciences Share Price Target - Next Week
| Level | Value | Analysis |
|---|---|---|
| Next Week Target 3 | 978.42 (+3.29%) | Fibonacci Extension Level 64.90% |
| Next Week Target 2 | 968.4 (+2.23%) | Price Action: 14 Aug 2025 High |
| Next Week Target 1 | 958.55 (+1.19%) | Fibonacci Extension Level 23.60% |
| Current Price | 947.20 | Glenmark Life Sciences's share price as of 29 Aug 2025 |
| Stop Loss 1 | 943.9 (-0.35%) | Price Action: 26 Aug 2025 Low |
| Stop Loss 2 | 933.4 (-1.46%) | Price Action: 09 Apr 2025 Low |
| Stop Loss 3 | 920.1 (-2.87%) | Price Action: Aug 2025 Low |
Weekly Target Summary
For next week, our analysis suggests a potential movement range of -2.86% to 3.30% with:
- Upper targets: ₹958.55 to ₹978.42
- Support levels: ₹943.9 to ₹920.1
Glenmark Life Sciences Share Price Target - Next Month
| Level | Value | Analysis |
|---|---|---|
| Next Month Target 3 | 1040.5 (+9.85%) | Price Action: 25 Apr 2025 High |
| Next Month Target 2 | 1030 (+8.74%) | Price Action: 21 Apr 2025 High |
| Next Month Target 1 | 1019.8 (+7.66%) | Price Action: 06 Jun 2025 High |
| Current Price | 947.20 | Glenmark Life Sciences's share price as of 29 Aug 2025 |
| Stop Loss 1 | 927.4 (-2.1%) | Price Action: 11 Apr 2025 Low |
| Stop Loss 2 | 906 (-4.34%) | Price Action: Feb 2024 High |
| Stop Loss 3 | 882 (-6.89%) | Price Action: Jun 2024 High |
Monthly Target Summary
Looking ahead to next month, technical analysis indicates:
- Potential price movement: -6.88% to 9.85% with:
- Target range: ₹1019.8 to ₹1040.5
- Support levels: ₹927.4 to ₹882
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
